Galera Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019	2018	2017
Selling, General & Admin	22.84	20.21	20.95	15.71	8.36	5.59	3.5
Research & Development	24.12	31.01	52.42	54.85	42.33	18.66	20.59
Other Operating Expenses	2.31	0	0	0	0	0	0
Operating Expenses	49.26	51.23	73.37	70.55	50.69	24.26	24.09
Operating Income	-49.26	-51.23	-73.37	-70.55	-50.69	-24.26	-24.09
Interest Expense / Income	11.41	11.57	7.19	4.88	3.03	0.22	0
Other Expense / Income	-1.59	-0.51	-0.03	-1.2	-1.78	-0.58	-0.19
Pretax Income	-59.08	-62.29	-80.53	-74.23	-51.94	-23.9	-23.91
Income Tax	0	-0.07	0	-0.02	-0.01	-0.22	-0.36
Net Income	-59.08	-62.22	-80.53	-74.22	-51.93	-23.68	-23.55
Preferred Dividends	0	0	0	0	7.18	5.91	4.59
Net Income Common	-59.08	-62.22	-80.53	-74.22	-59.11	-29.59	-28.13
Shares Outstanding (Basic)	45	27	26	25	4	0	0
Shares Outstanding (Diluted)	45	27	26	25	4	0	0
Shares Change	64.47%	5.03%	3.70%	586.06%	1105.94%	-	-
EPS (Basic)	-1.33	-2.30	-3.12	-2.98	-16.31	-98.42	-93.59
EPS (Diluted)	-1.33	-2.30	-3.12	-2.98	-16.31	-98.42	-93.59
Free Cash Flow	-44.91	-43.45	-68.24	-59.99	-47.29	-22.51	-23.73
Free Cash Flow Per Share	-1.01	-1.60	-2.65	-2.41	-13.05	-74.89	-78.93
EBITDA	-47.41	-50.61	-72.56	-68.99	-48.64	-23.55	-23.82
Depreciation & Amortization	0.26	0.11	0.78	0.37	0.27	0.13	0.08
EBIT	-47.67	-50.72	-73.34	-69.35	-48.91	-23.68	-23.91

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).